European Metropolitan Area of Munich Is Top Location for Biotechnology and Pharmaceutical Industries
The biotech sector in the Greater Munich area continues to demonstrate significant growth in revenue and staff numbers despite ever-increasing international competition. This continues Munich's status as one of the pre-eminent locations for this future-oriented industry. This was confirmed by the latest study done by the City of Munich, the IHK and BioMGmbH based on a survey and questionaire of different businesses and experts.
In 2013, 23,000 people were working here in a total of 377 biotechnology and pharmaceutical companies, generating a turnover of around 8.5 billion euro (not including companies from the medical engineering sector). This is in addition to around 10,000 employees in public and private research facilities and universities.
According to criteria set out by the OECD, around 15 % of German biotechnology firms have their headquarters in the Greater Munich area, with 30% of the nation's biotechnological development of drugs taking place here.
"This study shows that companies in Munich have done an excellent job of getting through the difficult times and that the international appeal of this location has been boosted even further", says the Head of the Department for Work and Economy, Mayor Josef Schmid, and he continues: "The economic success of this sector is not only based on an outstanding scientific community but also on recognised and effective management of the network."
The local nucleus of companies researching, developing and manufacturing therapeutic and diagnostic agents comprises the area around the IZB (Innovation and Start-Up Centre for Biotechnology) in Martinsried, in South-West Munich and its administrative district (see map). A particularly heavyweight contender is found further South in Penzberg in the form of Roche Diagnostics: these are the largest entities in Europe dedicated to the research, development and manufacture of biopharmaceuticals and diagnostic agents, and with their 5100+ employees they contribute a significant amount to the character of this biotechnology cluster.
According to a ranking of “Genetic Engineering & Biotechnology News, GEN”, March 2014, the greater Munich region ranks within the TOP 9–10 of all listed US clusters when looking at employment, public funding and granted patents.
An upbeat mood prevails in the Greater Munich area for this sector: around 75% of companies located here are expecting continuous improvements in their business situation until 2017. More than 20% of them assume at the very least that the current situation will stabilise further.
Dr Horst Domdey, Managing Director of BioM Biotech Cluster Development GmbH comments on these results: "The scale of networking between scientific organisations, as well as with industry is huge, as the rates of satisfaction reflected in the survey have clearly shown. That having been said, there is always room for further improvement and we constantly have to respond to new demands. A special challenge lies in introducing the region to notable global trends at an early enough stage, and in developing a solid competitive position as we managed to do in the field of 'personalised medicine.'"
The study shows that companies are highly diversified in terms of science and technology and are able to assimilate new trends quickly and successfully. During the last few years, a number of businesses have relocated from the US, Japan and India, demonstrating Munich's appeal as a centre for research, development and sales. This wave of relocation to Munich included Actavis, Exosome Diagnostics, Myriad Genetics, Vertex and Panacea Biotec.
Crucial in this respect are both a qualified workforce and outstanding scientific studies that generate a steady supply of fresh energy for new technological applications and product ideas. The company Morphosis is the perfect example of a leading global technology provider, as demonstrated by around 70 research projects with global Big Pharma partners. In terms of financial volume, huge business acquisitions over the last few years have in fact not led to "expertise being sold off", but have generally encouraged the new parent company to forge even stronger ties with Munich as a great location for this sector. Since its takeover of the biotech company Micromet, the research facility run by Amgen in Munich is now their largest outside of the US. Daichii Sankyo has commissioned the development of its biotechnological oncology pipeline in Martinsried and has laid the foundations for this by acquiring U3 Pharma.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance